Browse the evidence

Once-weekly subcutaneous administration of the glucagon/GLP-1 receptor co-agonist NNC9204-1177 produces dose-dependent, clinically significant body weight loss in adults with overweight or obesity, but is associated with unacceptable safety concerns including increased heart rate, hepatic disturbances, and impaired glucose tolerance.

This specific drug (NNC9204-1177) is not available for clinical use because it caused unacceptable side effects like increased heart rate and liver issues, despite causing significant weight loss. However, it highlights that combining GLP-1 and glucagon pathways can lead to substantial weight loss, which is why other approved GLP-1 medications exist. If you are considering GLP-1 therapy, discuss the specific safety profile of the approved options with your healthcare provider.

A baseline triglyceride/HDL ratio of ≤ 3.0 predicts a high probability of successful anti-diabetic medication dose reduction following intentional weight loss in overweight/obese type 2 diabetic patients.

If you have Type 2 Diabetes and are planning to lose weight, ask your doctor to check your Triglyceride/HDL ratio before starting. A ratio of 3 or lower suggests you are highly likely to successfully reduce your diabetes medication dosage as you lose weight. This helps set realistic expectations and motivates the weight loss effort.

Omega-3 supplementation combined with aerobic exercise may enhance fat loss compared to exercise alone, primarily by upregulating lipid oxidative enzymes and downregulating lipogenic gene expression via PPAR-α activation.

If you are doing regular aerobic exercise, adding Omega-3s (around 3-6g/day of fish oil) might give you a slight edge in fat loss compared to exercise alone. However, do not expect dramatic results if you are not exercising or eating in a caloric deficit. The evidence is mixed, so prioritize your training and diet first.

Omega-3 supplementation may improve exercise performance by enhancing blood flow to working muscles through increased brachial artery diameter and improved red blood cell deformability.

Taking Omega-3s may help your blood vessels dilate better during exercise, which supports endurance. However, do not expect this to make you run faster or lift heavier directly. It is a supportive health measure, not a performance enhancer.

Omega-3 supplementation may reduce delayed-onset muscle soreness (DOMS) and improve recovery by modulating inflammatory eicosanoids and increasing blood flow.

Omega-3s might help reduce muscle soreness after intense workouts, but the evidence is not consistent. Do not rely on them to eliminate soreness. Prioritize sleep, hydration, and protein intake for recovery.

Oral semaglutide (up to 7 mg/day) produces significant weight loss (mean 4.5 kg) and BMI reduction in psychiatric patients with antipsychotic-induced weight gain over 16 weeks, with a safety profile comparable to metformin.

For psychiatric patients struggling with weight gain from antipsychotics, oral semaglutide is a viable treatment option. Start with 3 mg daily for the first month, then increase to 7 mg daily if tolerated. Expect about 4.5 kg (10 lbs) of weight loss over 4 months. Side effects like nausea are common but usually mild and go away. This treatment does not worsen psychiatric symptoms and may even improve quality of life.

Combined blockade of GDF8 (myostatin) and Activin A using monoclonal antibodies significantly increases lean muscle mass and decreases fat mass in postmenopausal women, with effects reversing to baseline upon cessation of treatment.

For postmenopausal women seeking to increase muscle mass, blocking both myostatin and activin A via antibody therapy produces significant muscle growth and fat loss. However, this effect is not permanent; stopping treatment leads to a return to baseline muscle size within about 6 months. The treatment requires regular IV infusions and carries mild side effects like muscle spasms. It is not a lifestyle intervention but a medical therapy requiring clinical supervision.

High-intensity interval training (HIIT) or resistance training (RT) is safe and effective for patients with muscle Carnitine Palmitoyl-Transferase II (CPTII) deficiency because these activities rely on glycogen/phosphocreatine pathways rather than long-chain fatty acid oxidation, thereby avoiding rhabdomyolysis triggers.

If you have CPTII deficiency, do not avoid exercise entirely. Instead of long, steady-state cardio (like running or cycling) which relies on fat burning, focus on resistance training and high-intensity intervals (like sprints or circuit training). These activities use glycogen, which your muscles can still process safely. Start with moderate intensity (around 70% of your max capacity) and build up gradually under supervision.

In carriers of the BDNF rs10835211 GG genotype, high carbohydrate intake (>48% of energy) is associated with lower fat-free mass and skeletal muscle mass compared to lower intake, whereas high fiber intake (>18g/day) is associated with higher fat-free mass but also higher total cholesterol and LDL-C.

If you carry the BDNF rs10835211 GG genotype, your body composition response to macronutrients differs from the general population. High carbohydrate intake (>48% of calories) may be associated with lower muscle mass in this group. However, ensuring adequate fiber intake (>18g/day) may support higher fat-free mass, though it was also linked to higher cholesterol in this specific study. Focus on fiber-rich carbohydrate sources and monitor lipid profiles.

In BDNF rs10835211 GG genotype carriers, high protein intake (>18% of energy) is associated with higher waist circumference, BMI, body fat, and insulin resistance (HOMA-IR), while high fat intake (>30% of energy) is associated with higher visceral adipose tissue (VAT) and HDL-C.

If you carry the BDNF rs10835211 GG genotype, be cautious with high-protein (>18% energy) and high-fat (>30% energy) diets. This study links these intake levels in this group to higher waist circumference, visceral fat, and insulin resistance. Consider balancing these macros and monitoring waist circumference and fasting insulin.

In BDNF rs10835211 GG genotype carriers, higher daily energy intake (>1800 kcal) is associated with lower fasting insulin, lower HbA1c, and lower HOMA-IR compared to lower energy intake, despite similar or higher body weight.

If you carry the BDNF rs10835211 GG genotype, restricting calories too severely (<1800 kcal) might be associated with higher insulin resistance and HbA1c. Ensure you are eating enough to support your metabolic health, as this group may respond differently to caloric restriction.

A multimodal lifestyle intervention combining energy-restricted diet (plate model) and increased physical activity produces limited, non-sustained weight loss (~2.5 kg) in primary care settings, with no significant difference between intensive and standard care protocols.

Standard lifestyle advice (diet and exercise) in primary care leads to modest weight loss (approx. 2.5 kg) over a year, regardless of how much extra support or counseling you receive. While this is better than doing nothing, it is often insufficient for significant health improvements, and maintaining the regimen is difficult for most people. Focus on sustainable habits rather than intensive, short-term protocols.

Female resistance-trained athletes tend to spare more lean mass than males during caloric restriction, potentially due to differences in training experience, pre-diet volume, and energy deficit.

Female athletes may naturally preserve muscle better during a cut than males, but they should still prioritize high training volume to maximize this benefit.

Intensive Weight Management Programmes (IWMPs) utilizing Total Diet Replacement (TDR) achieve substantial, sustained weight loss (5-15%) and metabolic improvements in populations with obesity and type 2 diabetes, though specific evidence for women with PCOS is currently insufficient.

For women with PCOS, standard diet and exercise advice often fails to produce lasting metabolic benefits. Intensive programs using meal replacements (TDR) for a few months, followed by a structured return to food, can produce significant weight loss (5-15%) and improve metabolic health. However, because specific studies on PCOS are lacking, this approach should be considered promising but unproven for this specific group, requiring careful monitoring.

Quercetin supplementation at 1000 mg/day for >7 days accelerates recovery of muscle function and reduces muscle soreness and oxidative stress after intense exercise.

If you engage in intense exercise that causes muscle damage, taking 1000 mg of quercetin daily for at least 7 days (up to 12 weeks) may help reduce muscle soreness and speed up recovery. This is generally considered safe for young adults.

Adults with type 2 diabetes and high baseline glycemic risk (HbA1c >9%) experience the greatest improvements in glycemic control, physical health, and mental health from a 12-week multichannel digital health coaching program compared to those with lower baseline risk.

If you have Type 2 Diabetes and your HbA1c is above 9%, a structured 12-week digital coaching program involving weekly phone calls and text-based goal tracking is likely to significantly lower your blood sugar and improve your physical and mental health. If your HbA1c is already well-controlled (below 7%), you may not see significant changes in blood sugar, though you might still benefit from reduced diabetes distress.

Individuals previously engaged in resistance training can maintain participation during lockdown-induced facility closures by adapting to home-based modalities (bodyweight, minimal equipment) and full-body routines, though this adaptation is associated with reduced perceived effort, enjoyment, and motivation.

If your gym is closed, don't stop training. You can maintain your resistance training habits at home by switching to bodyweight exercises or using whatever equipment you have. Expect that it might feel easier and less enjoyable than before, and that your motivation might dip. This is normal. Focus on consistency rather than trying to replicate the exact intensity or equipment of your gym sessions. Most people can keep training even with these constraints.

Higher frequency, power-focused intensity, and traditional strength training programs yield superior improvements in walking capacity, speed, and quality of life compared to other prescriptions.

To get the most out of strength training after a stroke, focus on moving quickly (power) rather than just lifting heavy weights. Aim for more frequent sessions and traditional exercises that target specific muscle groups. This approach has been shown to significantly improve walking speed and quality of life.

Adherence to a ketogenic-like diet (KLD) results in a transient increase in LDL cholesterol but a sustained improvement in the triglyceride-to-HDL ratio (log(TG/HDL)), indicating a shift toward a less atherogenic LDL profile compared to ultra low-fat diets (ULF).

If you follow a very low-carb diet and see your LDL cholesterol rise, do not automatically assume your heart risk has increased. Look at your Triglyceride-to-HDL ratio; if it has improved significantly, it suggests your LDL particles have become larger and less harmful, which is a positive metabolic shift. Maintain your diet quality by minimizing added sugars and refined grains.

Both ketogenic-like (KLD) and ultra low-fat (ULF) diets produce similar weight loss and improvements in insulin resistance when adhered to, regardless of macronutrient composition.

You can lose significant weight and improve insulin resistance on either a very low-carb or a very low-fat diet, provided you stick to it. The specific macronutrient ratio matters less than your ability to maintain the diet and create a caloric deficit. Choose the pattern that allows you to minimize added sugars and refined grains while maximizing vegetables.

Tirzepatide demonstrates superior efficacy compared to Semaglutide in reducing HbA1c levels, but shows no clear superiority in weight loss or FBS reduction.

If your current Semaglutide treatment is not lowering your HbA1c enough, switching to Tirzepatide may provide better blood sugar control. However, do not expect significantly more weight loss from this switch, as both drugs appear to offer similar weight reduction benefits in this analysis.

Switching from Liraglutide to Semaglutide results in significant additional weight loss and FBS reduction, but does not significantly impact HbA1c levels.

If you are currently on Liraglutide and struggling with weight or fasting blood sugar, switching to Semaglutide may help you lose more weight and lower your FBS. However, this switch is unlikely to significantly improve your HbA1c levels.

Moderate consumption of dairy products, particularly fermented dairy like yogurt, is associated with reduced cardiovascular risk and lower long-term weight gain, contrary to historical concerns about saturated fat.

You can include moderate amounts of dairy in your diet, especially fermented options like yogurt and cheese. They are linked to lower cardiovascular risk and weight gain. Avoid very high intake (>1000g/day).

A hybrid intensive lifestyle intervention (HM) combining 2 in-person and 10 virtual sessions is as effective as fully in-person or fully virtual models for reducing body weight and improving glycemic control in patients with diabetes and obesity over 12 weeks.

If you have diabetes and obesity, a hybrid lifestyle program that mixes a few clinic visits with online coaching can help you lose weight and control blood sugar just as well as going to the clinic every week. This approach saves you travel time and money while still providing the necessary medical supervision and support to succeed.